Concluded an agreement to transfer the manufacturing facility of Asia and Sista Genix to SKYPE
Tuesday, September 18, 2018
Ascenti announced today a contract to sell our advanced wound dressing manufacturing facility located in the UK's Gargleave to SKYPE HEALTHCARE. With the transfer of the facility due to completion of the transaction, more than 350 employees will transfer to SKYPE and will support the manufacturing contract with KCI, an affiliate affiliated company. The manufacturing contract guarantees the ongoing supply of critical products and components that advance KCI's global growth strategy on Advanced Wound Dressing (AWD).
As soon as the transaction is completed, the manufacturing, sterilization services, warehouse facilities, research and development, and regulatory support functions in the UK's Garuglave will be transferred to SKYPE · Healthcare.
This strategic deal based on the recent momentum of Crawford Healthcare acquisition by Asset will further strengthen KCI's position as a world leader in advanced wound care. KCI can strengthen its focus on marketing and commercialization in the growing AWD business while relying on SKYPE's manufacturing expertise in key product lines through the transfer of the Gargleave facility.
R. Andrew · Eckertt, president and chief executive officer (CEO) of Assette, said: "The global market for advanced wound care is growing rapidly, expanding KCI's AWD collagen dressing portfolio, including the market leading collagen dressing PROMOGRAN PRISMA ™ Matrix and superabsorbent KerraMax Care® series , Complementing our negative pressure wound treatment products to make them more complete is very important for our growth goals.This transaction enables us to maintain and expand innovation and product development activities, While concentrating on the commercial practice of the business, we will be able to make strategic investments to expand our business in other fields such as digital wound care / surgical solutions leading by our company. "
Acetity will continue to operate the facilities of Gargleve until the transaction is completed. Acetity expects transactions to be completed in early October 2018.
About Acetity
As a global company dealing with advanced wound care technology, Ashley is committed to developing innovative healing solutions for customers and patients for a series of treatments. Our subsidiary KCI is the most trusted brand in advanced wound care. KCI's product portfolio, which does not allow other companies to follow, can be offered in more than 90 countries and will provide value through an industry-leading solution in terms of quality, safety and customer experience, improving healing speed. KCI, committed to advancing the science of healing, sets standards leading to innovation in advanced wound care.
The official version of this press release is the original language version. The translation language version is provided for the convenience of the reader and has no legal effect. When using the translation language version as a document, please compare it with the original language version which is the only version with legal effect.
Contacts
Acelity
Kathryn Skeen, +1-210-882-2067
Corporate Communications
kathryn.skeen@acelity.com
or
Jathan Tucker, +1-210-255-6816
Investor Relations
jathan.tucker@acelity.com